Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vertex Pharmaceuticals price target raised to $280 from $275 at Argus » 07:42
06/13/22
06/13
07:42
06/13/22
07:42
VRTX

Vertex Pharmaceuticals

$254.86 /

-4.85 (-1.87%)

Argus analyst Jasper…

Argus analyst Jasper Hellweg raised the firm's price target on Vertex Pharmaceuticals to $280 from $275 and keeps a Buy rating on the shares. The company continues to benefit from high sales of Trikafta, as well as its pipeline progress and partnerships with other organizations, the analyst tells investors in a research note. Hellweg adds that while Vertex is now able to treat most of the 80,000 cystic fibrosis patients in North America, Europe, and Australia, the company's management believes that it could treat up to 90% of all people with CF if it receives approval for expanded indications.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

06/13/22 Cowen
Vertex Pharmaceuticals price target raised to $310 from $305 at Cowen
06/13/22 Stifel
Crispr Therapeutics price target raised to $57 from $52 at Stifel
06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

Recommendations
Vertex Pharmaceuticals price target raised to $310 from $305 at Cowen » 07:39
06/13/22
06/13
07:39
06/13/22
07:39
VRTX

Vertex Pharmaceuticals

$254.86 /

-4.85 (-1.87%)

Cowen analyst Philip…

Cowen analyst Philip Nadeau raised the firm's price target on Vertex Pharmaceuticals to $310 from $305 and keeps an Outperform rating on the shares. The analyst noted they presented updated data from exa-cel's pivotal trials in TDT and SCD and he noted exa-cel continues to produce strong efficacy with acceptable safety. He added exa-cel estimates to his model and raised his price target.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

06/13/22 Stifel
Crispr Therapeutics price target raised to $57 from $52 at Stifel
06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

Recommendations
Crispr Therapeutics price target raised to $57 from $52 at Stifel » 07:05
06/13/22
06/13
07:05
06/13/22
07:05
CRSP

Crispr Therapeutics

$63.78 /

-7.92 (-11.05%)

, VRTX

Vertex Pharmaceuticals

$254.86 /

-4.85 (-1.87%)

, BLUE

Bluebird Bio

$3.73 /

+ (+0.00%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett raised the firm's price target on Crispr Therapeutics (CRSP) to $57 from $52 and keeps a Hold rating on the shares after Vertex Pharmaceuticals (VRTX) and Crispr announced the presentation of new data on exa-cel, formerly known as CTX001, from the CLIMB-111, CLIMB-121 and CLIMB-131 studies at EHA 2022. Though durability in SCD may come under scrutiny, Burnett calls the updated data that includes more patients and follow-up "great and in line with current high expectations for the program." In addition, he thinks the FDA advisory committee on Bluebird Bio's (BLUE) beti-cel is "a great outcome" for Vertex and Crispr, said Burnett, who has updated his CTX001 forecast, which yields his higher target.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

BLUE Bluebird Bio
$3.73 /

+ (+0.00%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

05/23/22 Piper Sandler
Crispr Therapeutics price target lowered to $115 from $180 at Piper Sandler
05/17/22 Citi
Crispr Therapeutics price target lowered to $53 from $64 at Citi
05/13/22 Needham
Crispr Therapeutics price target lowered to $122 from $170 at Needham
05/11/22 Oppenheimer
Crispr Therapeutics price target lowered to $150 from $172 at Oppenheimer
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
BLUE Bluebird Bio
$3.73 /

+ (+0.00%)

06/10/22 SVB Leerink
Positive AdComm for eli-cel a 'win' for Bluebird Bio, says SVB Leerink
06/08/22 Morgan Stanley
Morgan Stanley sees risk to positive vote in both Bluebird Bio AdComs
06/07/22 Goldman Sachs
Goldman says AdCom briefing documents question Bluebird Bio's LVV platform
05/10/22 Barclays
Bluebird Bio price target lowered to $3 from $4 at Barclays
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

BLUE Bluebird Bio
$3.73 /

+ (+0.00%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

BLUE Bluebird Bio
$3.73 /

+ (+0.00%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

BLUE Bluebird Bio
$3.73 /

+ (+0.00%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

Hot Stocks
Vertex, Crispr Therapeutics present new data on exa-cel » 15:24
06/12/22
06/12
15:24
06/12/22
15:24
VRTX

Vertex Pharmaceuticals

$254.86 /

-4.85 (-1.87%)

, CRSP

Crispr Therapeutics

$63.78 /

-7.92 (-11.05%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics (CRSP) announce presentation of new data on exa-cel, formerly known as CTX001, from CLIMB-111, CLIMB-121 and CLIMB-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia or severe sickle cell disease and provided additional program updates. The data presented at the European Hematology Association Congress are from 75 patients - 44 with TDT and 31 with SCD - with follow-up ranging from 1.2 to 37.2 months after exa-cel dosing. Of the 44 patients with TDT, 26 had beta-zero/beta-zero or other beta-zero-like severe genotypes. Forty-two of 44 patients with TDT were transfusion-free with follow-up ranging from 1.2 to 37.2 months after exa-cel infusion. Two patients who were not yet transfusion-free had 75% and 89% reductions in transfusion volume. TDT patients had substantial mean increases in fetal hemoglobin and corresponding increases in mean total hemoglobin with mean total Hb levels increasing to greater than11 g/dL by Month 3 and maintained thereafter. All 31 patients with severe SCD characterized by recurrent vaso-occlusive crises were free of VOCs after exa-cel infusion through duration of follow-up, with follow-up ranging from 2.0 to 32.3 months. SCD patients had mean HbF of approximately 40% by Month 4 and maintained thereafter. The safety was generally consistent with myeloablative conditioning with busulfan and autologous stem cell transplant. All patients engrafted neutrophils and platelets after exa-cel infusion. Among the 44 patients with TDT, two patients had serious adverse events considered related to exa-cel. As previously reported, one patient had three SAEs considered related to exa-cel, hemophagocytic lymphohistiocytosis, acute respiratory distress syndrome and headache, and one SAE of idiopathic pneumonia syndrome that was considered related to both exa-cel and busulfan. All four SAEs occurred in the context of HLH and have resolved. One patient had SAEs of delayed neutrophil engraftment and thrombocytopenia, both of which were considered related to exa-cel and busulfan, and both SAEs have resolved. Among the 31 patients with SCD, there were no SAEs considered related to exa-cel. Following ongoing discussions with regulators, the clinical trial protocols for CLIMB-111 and CLIMB-121 were amended to incorporate feedback on the primary endpoints for regulatory submission. Specifically, the primary endpoint in CLIMB-111 for TDT has been amended from proportion of subjects achieving transfusion reduction after exa-cel infusion to proportion of subjects maintaining weighted average Hb greater than or equal to9 g/dL without red blood cell transfusions for at least 12 consecutive months after exa-cel infusion. The primary endpoint in CLIMB-121 for SCD has been updated from proportion of subjects with HbF greater than or equal to20% after exa-cel infusion, to proportion of subjects who have not experienced any severe VOCs for at least 12 consecutive months after exa-cel infusion. Both clinical trials are now in Phase 3 and are fully enrolled. All patients will have the opportunity to join CLIMB-131, a long-term follow-up study, after completing participation in the initial studies. In line with the company's strategy of developing therapies for patients of all ages, two additional Phase 3 studies of exa-cel have begun. Earlier this year, the Independent Data Monitoring Committee met to review the data in adults and adolescents and endorsed expanding into younger pediatric patients. CLIMB-141 and CLIMB-151 are Phase 3 open-label trials designed to assess the safety and efficacy of a single dose of exa-cel in patients ages 2 to 11 years with TDT or SCD, respectively. The trials are now open for enrollment and currently enrolling patients ages 5 to 11 years and will plan to extend to patients 2 to less than 5 years of age at a later date. Each trial will enroll approximately 12 patients. Patients will be followed for approximately two years after infusion. Each patient will be asked to participate in CLIMB-131, a long-term follow-up trial. Vertex also presented three additional abstracts on the burden of disease in sickle cell disease and beta thalassemia at the EHA Congress.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

05/23/22 Piper Sandler
Crispr Therapeutics price target lowered to $115 from $180 at Piper Sandler
05/17/22 Citi
Crispr Therapeutics price target lowered to $53 from $64 at Citi
05/13/22 Needham
Crispr Therapeutics price target lowered to $122 from $170 at Needham
05/11/22 Oppenheimer
Crispr Therapeutics price target lowered to $150 from $172 at Oppenheimer
VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

VRTX Vertex Pharmaceuticals
$254.86 /

-4.85 (-1.87%)

CRSP Crispr Therapeutics
$63.78 /

-7.92 (-11.05%)

Hot Stocks
Vertex Pharmaceuticals to present data on treatment with CFTR modulators » 11:03
06/10/22
06/10
11:03
06/10/22
11:03
VRTX

Vertex Pharmaceuticals

$255.08 /

-4.63 (-1.78%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals announced that five scientific abstracts on the company's portfolio of cystic fibrosis medicines will be presented at the European Cystic Fibrosis Society's 45th European Cystic Fibrosis Conference held June 8-11, 2022, in Rotterdam, the Netherlands. Vertex will present the first analysis of data collected in the U.S. CF Foundation Patient Registry of over 16,000 people with CF treated with TRIKAFTA for an average of nine months. This first interim analysis of an ongoing five-year post-authorization study showed that real-world treatment with TRIKAFTA was associated with improved lung function and a 77% reduced risk of pulmonary exacerbations compared to pre-TRIKAFTA baseline, as well as an 87% lower risk of lung transplant and a 74% lower risk of death, compared to the historical 2019 U.S. CFFPR population. No new safety concerns were identified. Vertex will also present data comparing the annual rate of lung function change in people with CF ages 12 years and older with two F508del mutations or one F508del mutation and one minimal function mutation treated with TRIKAFTA in pivotal studies and an open-label extension study compared to propensity-score matched historical CFTR-modulator-untreated controls from the U.S. CFFPR. Results show that TRIKAFTA demonstrated on average no decrease in ppFEV1 over a two-year period in this population, in contrast to declines seen in the matched controls. The analysis indicates that treatment with TRIKAFTA has a significant impact on the trajectory of CF lung disease. Additionally, Vertex will present data from a long-term real-world study demonstrating that initiating KALYDECO early in life preserves lung function to a greater extent than if KALYDECO is initiated at an older age. These results show the importance of early initiation of KALYDECO for eligible patients.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

VRTX Vertex Pharmaceuticals
$255.08 /

-4.63 (-1.78%)

Hot Stocks
Vertex Pharmaceuticals announces VX-147 granted BTD by US, PRIME by EMA » 08:13
06/08/22
06/08
08:13
06/08/22
08:13
VRTX

Vertex Pharmaceuticals

$271.87 /

+3.89 (+1.45%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, has granted inaxaplin, VX-147, Breakthrough Therapy Designation, BTD, for APOL1-mediated focal segmental glomerulosclerosis and the European Medicines Agency, EMA, has granted inaxaplin Priority Medicines, PRIME, designation for APOL1-mediated chronic kidney disease. Inaxaplin is the first investigational therapy aimed at treating the underlying cause of AMKD. Vertex now holds three of the approximately 70 non-oncological PRIME designations granted to date, including its two PRIME designations for exagamglogene autotemcel, formerly known as CTX001, one for transfusion-dependent beta thalassemia and one for sickle cell disease. In the US, this is the ninth breakthrough therapy designation granted to Vertex across its portfolio programs.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

VRTX Vertex Pharmaceuticals
$271.87 /

+3.89 (+1.45%)

Hot Stocks
Vertex Pharmaceuticals presents data from VX-880 Phase 1/2 clinical trial » 10:03
06/06/22
06/06
10:03
06/06/22
10:03
VRTX

Vertex Pharmaceuticals

$269.93 /

+0.47 (+0.17%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals provided additional data on patients dosed in Part A of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia. As reported last month, both patients treated with half the target dose of VX-880 achieved glucose-responsive insulin production, improvements in glycemic control and reductions in exogenous insulin requirements. The data presented today show significant increases in the blood glucose time-in-range compared to baseline, following treatment with VX-880. Time spent in target range is a clinically important metric in diabetes management that reflects the amount of time a patient's blood glucose level is measured in the desired, target blood sugar range. The accepted American Diabetes Association/European Association for the Study of Diabetes target for time-in-range is 70%. These data were presented during the American Diabetes Association 82nd Scientific Sessions Conference on June 6, 2022 in New Orleans, Louisiana from 9:00 to 9:15 a.m. CDT as an oral abstract presentation, "Stem Cell-Derived, Fully Differentiated Islet Cells for Type 1 Diabetes". The presentation included data from both patients dosed in Part A of the study, designed to assess the safety profile of VX-880 at half the target dose. Patient 1 showed a blood glucose time-in-range increase from 40.1% at baseline to 99.9% at Day 270 and was insulin independent. Patient 2 showed a time-in-range increase from 35.9% at baseline to 51.9% at Day 150 with a 30% reduction in exogenous insulin use. VX-880 has been generally well tolerated in all patients dosed to date, with the majority of adverse events being mild or moderate. Additional Vertex presentations at ADA this year included an oral presentation, "Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies", and poster, "Gaps Remain in Achieving Target T1D Glycemic Goals Despite Advanced Technologies". To date, three patients have been dosed in the Phase 1/2 study with VX-880. Two patients received half the target dose of cells in Part A of the study. A third patient has received the full target dose in Part B of the study. Vertex is also pursuing additional programs in T1D, including one in which these same stem cell-derived islets are encapsulated in an immunoprotective device to be surgically implanted without the use of concomitant immunosuppression, and another program where cells are modified to produce hypoimmune stem cell-derived islets. IND-enabling studies for the encapsulated cells program are underway, and the company remains on track to submit an IND in 2022.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

VRTX Vertex Pharmaceuticals
$269.93 /

+0.47 (+0.17%)

Hot Stocks
Vertex, Crispr Therapeutics say late-breaking CTX001 abstract accepted for EHA » 10:09
06/02/22
06/02
10:09
06/02/22
10:09
VRTX

Vertex Pharmaceuticals

$262.26 /

-7.35 (-2.73%)

, CRSP

Crispr Therapeutics

$58.06 /

-0.03 (-0.05%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association, or EHA, Congress. Late-breaking abstract #LB2367 entitled "Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent undefinedeta-Thalassemia and Severe Sickle Cell Disease," will be an oral presentation on Sunday, June 12. The abstract from Vertex and CRISPR Therapeutics includes data on patients treated in CLIMB-111 and CLIMB-121 and followed in CLIMB-131 with CTX001, now known as exagamglogene autotemcel, or exa-cel. This abstract has been selected for the media briefing program and is therefore embargoed until Saturday, June 11. Vertex also announced three abstracts accepted for poster presentation at EHA.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

CRSP Crispr Therapeutics
$58.06 /

-0.03 (-0.05%)

VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
CRSP Crispr Therapeutics
$58.06 /

-0.03 (-0.05%)

05/23/22 Piper Sandler
Crispr Therapeutics price target lowered to $115 from $180 at Piper Sandler
05/17/22 Citi
Crispr Therapeutics price target lowered to $53 from $64 at Citi
05/13/22 Needham
Crispr Therapeutics price target lowered to $122 from $170 at Needham
05/11/22 Oppenheimer
Crispr Therapeutics price target lowered to $150 from $172 at Oppenheimer
VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

CRSP Crispr Therapeutics
$58.06 /

-0.03 (-0.05%)

VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

VRTX Vertex Pharmaceuticals
$262.26 /

-7.35 (-2.73%)

CRSP Crispr Therapeutics
$58.06 /

-0.03 (-0.05%)

On The Fly
What You Missed On Wall Street On Wednesday » 16:26
06/01/22
06/01
16:26
06/01/22
16:26
SPGI

S&P Global

$332.10 /

-17.85 (-5.10%)

, CRM

Salesforce

$176.04 /

+15.44 (+9.61%)

, HPQ

HP Inc.

$40.32 /

+1.56 (+4.02%)

, DAL

Delta Air Lines

$39.53 /

-2.16 (-5.18%)

, OPA

Magnum Opus Acquisition

$9.79 /

-0.04 (-0.41%)

, RBAC

RedBall Acquisition

$9.95 /

+0.57 (+6.08%)

, TPX

Tempur Sealy

$24.65 /

-1.73 (-6.56%)

, VRTX

Vertex Pharmaceuticals

$269.61 /

+1.12 (+0.42%)

, BPMC

Blueprint Medicines

$55.98 /

+1.1 (+2.00%)

, GDRX

GoodRx

$7.51 /

-0.45 (-5.65%)

, MDT

Medtronic

$97.78 /

-2.39 (-2.39%)

, AAPL

Apple

$148.68 /

-0.13 (-0.09%)

, ENOB

Enochian Biosciences

$3.78 /

-1.475 (-28.10%)

, AFRM

Affirm

$24.31 /

-4.15 (-14.58%)

, SQ

Block

$81.91 /

-5.58 (-6.38%)

, TSLA

Tesla

$740.48 /

-17.53 (-2.31%)

, TWTR

Twitter

$39.31 /

-0.43 (-1.08%)

, META

Meta Platforms

/

+

, FB

Meta Platforms

$188.59 /

-4.965 (-2.57%)

, CPRI

Capri Holdings

$49.31 /

+0.55 (+1.13%)

, VSCO

Victoria's Secret

$44.92 /

+3.645 (+8.83%)

, AMBA

Ambarella

$83.59 /

-1.64 (-1.92%)

, APPS

Digital Turbine

$19.65 /

-5.82 (-22.85%)

, HUM

Humana

$447.44 /

-6.08 (-1.34%)

, CMAX

CareMax

$5.41 /

+0.73 (+15.60%)

, NIO

Nio

$17.57 /

+0.155 (+0.89%)

, LEVI

Levi Strauss

$18.38 /

+0.225 (+1.24%)

, ABC

AmerisourceBergen

$150.02 /

-4.775 (-3.08%)

Get caught up quickly on…

ShowHide Related Items >><<
VSCO Victoria's Secret
$44.92 /

+3.645 (+8.83%)

VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

TWTR Twitter
$39.31 /

-0.43 (-1.08%)

TSLA Tesla
$740.48 /

-17.53 (-2.31%)

TPX Tempur Sealy
$24.65 /

-1.73 (-6.56%)

SQ Block
$81.91 /

-5.58 (-6.38%)

SPGI S&P Global
$332.10 /

-17.85 (-5.10%)

RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

OPA Magnum Opus Acquisition
$9.79 /

-0.04 (-0.41%)

NIO Nio
$17.57 /

+0.155 (+0.89%)

META Meta Platforms
/

+

MDT Medtronic
$97.78 /

-2.39 (-2.39%)

LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

HUM Humana
$447.44 /

-6.08 (-1.34%)

HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

GDRX GoodRx
$7.51 /

-0.45 (-5.65%)

FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

ENOB Enochian Biosciences
$3.78 /

-1.475 (-28.10%)

DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

CRM Salesforce
$176.04 /

+15.44 (+9.61%)

CPRI Capri Holdings
$49.31 /

+0.55 (+1.13%)

CMAX CareMax
$5.41 /

+0.73 (+15.60%)

BPMC Blueprint Medicines
$55.98 /

+1.1 (+2.00%)

APPS Digital Turbine
$19.65 /

-5.82 (-22.85%)

AMBA Ambarella
$83.59 /

-1.64 (-1.92%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

ABC AmerisourceBergen
$150.02 /

-4.775 (-3.08%)

AAPL Apple
$148.68 /

-0.13 (-0.09%)

SPGI S&P Global
$332.10 /

-17.85 (-5.10%)

06/02/22 Deutsche Bank
S&P Global price target lowered to $418 from $483 at Deutsche Bank
06/02/22 BMO Capital
Moody's price target lowered to $309 from $331 at BMO Capital
06/02/22 BMO Capital
S&P Global price target lowered to $365 from $433 at BMO Capital
06/02/22 Morgan Stanley
Moody's price target lowered to $305 from $318 at Morgan Stanley
CRM Salesforce
$176.04 /

+15.44 (+9.61%)

06/02/22 Loop Capital
Salesforce price target lowered to $175 from $225 at Loop Capital
06/01/22 RBC Capital
Salesforce margin outlook overshadowed lower revenue guide, says RBC Capital
06/01/22 BMO Capital
Salesforce price target lowered to $225 from $260 at BMO Capital
06/01/22 Stifel
Salesforce price target lowered to $250 from $300 at Stifel
HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

06/01/22 Morgan Stanley
Morgan Stanley stays Underweight on HP Inc. after Q2 report
06/01/22 Citi
HP Inc. price target raised to $40 from $38 at Citi
06/01/22 Barclays
HP Inc. price target raised to $32 from $29 at Barclays
05/25/22 JPMorgan
HP Inc. price target lowered to $39 from $41 at JPMorgan
DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

06/01/22 Goldman Sachs
Delta Air Lines price target raised to $45 from $44 at Goldman Sachs
04/26/22 Northland
SpaceX's Starlink deal with Hawaiian highlights risk for Gogo, says Northland
04/22/22 Morgan Stanley
United Airlines price target raised to $67 from $62 at Morgan Stanley
04/22/22 JPMorgan
Delta Air Lines price target raised to $70 from $69 at JPMorgan
OPA Magnum Opus Acquisition
$9.79 /

-0.04 (-0.41%)

03/01/22 Benchmark
Magnum Opus Acquisition initiated with a Buy at Benchmark
12/15/21 Cantor Fitzgerald
Magnum Opus Acquisition price target raised to $14.50 from $10.00 at Cantor Fitzgerald
10/21/21 Cantor Fitzgerald
Magnum Opus Acquisition initiated with an Overweight at Cantor Fitzgerald
RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

TPX Tempur Sealy
$24.65 /

-1.73 (-6.56%)

06/01/22 Piper Sandler
Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler
04/12/22 Loop Capital
Tempur Sealy price target lowered to $28 from $35 at Loop Capital
04/06/22 Raymond James
Tempur Sealy price target lowered to $38 from $45 at Raymond James
04/01/22 Piper Sandler
Tempur Sealy price target lowered to $34 from $40 at Piper Sandler
VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
BPMC Blueprint Medicines
$55.98 /

+1.1 (+2.00%)

06/01/22 Jefferies
Blueprint Medicines raised to Buy at Jefferies after survey on Ayvakit in ISM
06/01/22 Jefferies
Blueprint Medicines upgraded to Buy from Hold at Jefferies
05/18/22 Piper Sandler
Blueprint Medicines price target lowered to $65 from $84 at Piper Sandler
05/04/22 Baird
Blueprint Medicines price target lowered to $96 from $123 at Baird
GDRX GoodRx
$7.51 /

-0.45 (-5.65%)

06/01/22 Baird
Baird downgrades GoodRx to Neutral amid disruption at Kroger
06/01/22 Baird
GoodRx downgraded to Neutral from Outperform at Baird
05/16/22 Baird
Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
05/12/22 Wells Fargo
GoodRx price target lowered to $9 from $20 at Wells Fargo
MDT Medtronic
$97.78 /

-2.39 (-2.39%)

06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
05/31/22 Raymond James
Medtronic price target lowered to $109 from $116 at Raymond James
05/31/22 Truist
Medtronic price target lowered to $111 from $121 at Truist
05/27/22 RBC Capital
Medtronic price target lowered to $122 from $135 at RBC Capital
AAPL Apple
$148.68 /

-0.13 (-0.09%)

06/01/22 Macquarie
Digital Turbine price target lowered to $40 from $70 at Macquarie
05/27/22 JPMorgan
iPhone China shipments in April below seasonal, says JPMorgan
05/25/22 Loop Capital
Loop Capital sees consensus for Apple's iPhone revenue in second half as low
05/24/22 BofA
Apple App Store growth has re-accelerated modestly, says BofA
ENOB Enochian Biosciences
$3.78 /

-1.475 (-28.10%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

05/23/22 Mizuho
April delinquency trends promising for Affirm, says Mizuho
05/17/22 Mizuho
Affirm price target lowered to $50 from $79 at Mizuho
05/16/22 Barclays
Affirm price target lowered to $35 from $65 at Barclays
05/13/22 RBC Capital
Affirm price target lowered to $48 from $58 at RBC Capital
SQ Block
$81.91 /

-5.58 (-6.38%)

06/01/22 Piper Sandler
App downloads for Block's Cash App strong, says Piper Sandler
05/24/22 Morgan Stanley
Morgan Stanley upgrades Marqeta to Overweight on attractive entry point
05/23/22 Truist
Block price target lowered to $145 from $165 at Truist
05/23/22 Deutsche Bank
Block price target lowered to $155 from $180 at Deutsche Bank
TSLA Tesla
$740.48 /

-17.53 (-2.31%)

06/01/22 Goldman Sachs
Tesla price target lowered to $1,000 from $1,200 at Goldman Sachs
05/31/22 Mizuho
Tesla shutdown in Shanghai a near-term headwind, says Mizuho
05/27/22 Credit Suisse
Tesla pullback brings attractive entry point, says Credit Suisse
05/26/22 Jefferies
Jefferies cuts Tesla price target on governance risk, challenging market
TWTR Twitter
$39.31 /

-0.43 (-1.08%)

06/02/22 Piper Sandler
Twitter price target raised to $54.,20 from $51.50 at Piper Sandler
05/24/22 Jefferies
Twitter price target lowered to $40 from $48 at Jefferies
05/24/22 Wedbush
More fireworks expected heading into Twitter shareholder meeting, says Wedbush
05/24/22 KeyBanc
Snap price target lowered to $27 from $45 at KeyBanc
META Meta Platforms
/

+

05/10/22 BMO Capital
Yelp price target lowered to $37 from $42 at BMO Capital
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
03/25/22 UBS
Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

06/02/22 Mizuho
Meta Platforms' Sheryl Sandberg difficult to replace, says Mizuho
06/02/22 Piper Sandler
Meta Platforms price target lowered to $220 from $230 at Piper Sandler
06/01/22 Morgan Stanley
Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
06/01/22 Morgan Stanley
Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
CPRI Capri Holdings
$49.31 /

+0.55 (+1.13%)

06/02/22 Credit Suisse
Capri Holdings price target lowered to $65 from $74 at Credit Suisse
06/02/22 Baird
Capri Holdings price target lowered to $75 from $85 at Baird
04/19/22 OTR Global
Tapestry view downgraded to Mixed from Positive at OTR Global
04/19/22 Barclays
Capri Holdings price target raised to $74 from $72 at Barclays
VSCO Victoria's Secret
$44.92 /

+3.645 (+8.83%)

06/02/22 Barclays
Victoria's Secret price target lowered to $60 from $61 at Barclays
06/01/22 JPMorgan
Victoria's Secret price target lowered to $57 from $71 at JPMorgan
06/01/22 Wells Fargo
Victoria's Secret price target lowered to $60 from $70 at Wells Fargo
05/16/22 JPMorgan
Victoria's Secret price target lowered to $71 from $86 at JPMorgan
AMBA Ambarella
$83.59 /

-1.64 (-1.92%)

06/02/22 Baird
Ambarella price target lowered to $125 from $200 at Baird
06/01/22 Craig-Hallum
Ambarella price target lowered to $100 from $170 at Craig-Hallum
06/01/22 Needham
Ambarella price target lowered to $120 from $175 at Needham
06/01/22 Morgan Stanley
Ambarella price target lowered to $114 from $122 at Morgan Stanley
APPS Digital Turbine
$19.65 /

-5.82 (-22.85%)

06/01/22 Craig-Hallum
Digital Turbine price target lowered to $85 from $105 at Craig-Hallum
06/01/22 Oppenheimer
Digital Turbine price target lowered to $40 from $117 at Oppenheimer
02/16/22 Roth Capital
Roth says Google news creates more unwarranted noise around Digital Turbine
HUM Humana
$447.44 /

-6.08 (-1.34%)

05/26/22 Bernstein
Humana resumed with a Market Perform at Bernstein
04/28/22 Wells Fargo
Humana price target raised to $512 from $491 at Wells Fargo
04/13/22 UBS
Humana upgraded to Buy from Neutral at UBS
04/07/22 Truist
Humana price target raised to $490 from $460 at Truist
CMAX CareMax
$5.41 /

+0.73 (+15.60%)

05/11/22 Cowen
CareMax price target lowered to $8 from $11 at Cowen
01/07/22 UBS
CareMax initiated with a Buy at UBS
12/01/21 Piper Sandler
Piper Sandler remains buyer of CareMax after management meeting
11/15/21 Piper Sandler
Piper remains buyer of CareMax, likes share setup into Q4
NIO Nio
$17.57 /

+0.155 (+0.89%)

05/23/22 Mizuho
Nio could be back to pre-shutdown levels by June, says Mizuho
05/16/22 BofA
Nio upgraded to Buy at BofA on 'brighter' second half view
05/16/22 BofA
Nio upgraded to Buy from Neutral at BofA
05/02/22 Morgan Stanley
Nio's April sales 'crimped' by lockdowns, says Morgan Stanley
LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

06/02/22 Stifel
Levi Strauss price target lowered to $26 from $30 at Stifel
04/11/22 JPMorgan
Levi Strauss price target lowered to $27 from $32 at JPMorgan
04/07/22 UBS
Levi Strauss price target lowered to $34 from $37 at UBS
04/07/22 Citi
Levi Strauss price target lowered to $27 from $28 at Citi
ABC AmerisourceBergen
$150.02 /

-4.775 (-3.08%)

05/27/22 Morgan Stanley
AmerisourceBergen target lowered to $175 at Morgan Stanley ahead of analyst day
05/26/22 Barclays
AmerisourceBergen upgraded to Overweight from Equal Weight at Barclays
05/25/22 Deutsche Bank
AmerisourceBergen price target lowered to $167 from $168 at Deutsche Bank
05/05/22 Baird
AmerisourceBergen price target raised to $187 from $179 at Baird
VSCO Victoria's Secret
$44.92 /

+3.645 (+8.83%)

VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

TWTR Twitter
$39.31 /

-0.43 (-1.08%)

TSLA Tesla
$740.48 /

-17.53 (-2.31%)

TPX Tempur Sealy
$24.65 /

-1.73 (-6.56%)

SQ Block
$81.91 /

-5.58 (-6.38%)

SPGI S&P Global
$332.10 /

-17.85 (-5.10%)

NIO Nio
$17.57 /

+0.155 (+0.89%)

MDT Medtronic
$97.78 /

-2.39 (-2.39%)

LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

HUM Humana
$447.44 /

-6.08 (-1.34%)

HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

GDRX GoodRx
$7.51 /

-0.45 (-5.65%)

FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

CRM Salesforce
$176.04 /

+15.44 (+9.61%)

CPRI Capri Holdings
$49.31 /

+0.55 (+1.13%)

CMAX CareMax
$5.41 /

+0.73 (+15.60%)

BPMC Blueprint Medicines
$55.98 /

+1.1 (+2.00%)

APPS Digital Turbine
$19.65 /

-5.82 (-22.85%)

AMBA Ambarella
$83.59 /

-1.64 (-1.92%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

ABC AmerisourceBergen
$150.02 /

-4.775 (-3.08%)

AAPL Apple
$148.68 /

-0.13 (-0.09%)

VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

TWTR Twitter
$39.31 /

-0.43 (-1.08%)

TSLA Tesla
$740.48 /

-17.53 (-2.31%)

SQ Block
$81.91 /

-5.58 (-6.38%)

OPA Magnum Opus Acquisition
$9.79 /

-0.04 (-0.41%)

NIO Nio
$17.57 /

+0.155 (+0.89%)

META Meta Platforms
/

+

MDT Medtronic
$97.78 /

-2.39 (-2.39%)

LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

HUM Humana
$447.44 /

-6.08 (-1.34%)

HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

ENOB Enochian Biosciences
$3.78 /

-1.475 (-28.10%)

DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

CRM Salesforce
$176.04 /

+15.44 (+9.61%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

ABC AmerisourceBergen
$150.02 /

-4.775 (-3.08%)

AAPL Apple
$148.68 /

-0.13 (-0.09%)

VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

TSLA Tesla
$740.48 /

-17.53 (-2.31%)

TPX Tempur Sealy
$24.65 /

-1.73 (-6.56%)

SQ Block
$81.91 /

-5.58 (-6.38%)

SPGI S&P Global
$332.10 /

-17.85 (-5.10%)

OPA Magnum Opus Acquisition
$9.79 /

-0.04 (-0.41%)

NIO Nio
$17.57 /

+0.155 (+0.89%)

META Meta Platforms
/

+

MDT Medtronic
$97.78 /

-2.39 (-2.39%)

LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

HUM Humana
$447.44 /

-6.08 (-1.34%)

HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

GDRX GoodRx
$7.51 /

-0.45 (-5.65%)

FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

CRM Salesforce
$176.04 /

+15.44 (+9.61%)

CPRI Capri Holdings
$49.31 /

+0.55 (+1.13%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

ABC AmerisourceBergen
$150.02 /

-4.775 (-3.08%)

AAPL Apple
$148.68 /

-0.13 (-0.09%)

VSCO Victoria's Secret
$44.92 /

+3.645 (+8.83%)

VRTX Vertex Pharmaceuticals
$269.61 /

+1.12 (+0.42%)

TWTR Twitter
$39.31 /

-0.43 (-1.08%)

TSLA Tesla
$740.48 /

-17.53 (-2.31%)

TPX Tempur Sealy
$24.65 /

-1.73 (-6.56%)

SQ Block
$81.91 /

-5.58 (-6.38%)

SPGI S&P Global
$332.10 /

-17.85 (-5.10%)

RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

NIO Nio
$17.57 /

+0.155 (+0.89%)

META Meta Platforms
/

+

MDT Medtronic
$97.78 /

-2.39 (-2.39%)

LEVI Levi Strauss
$18.38 /

+0.225 (+1.24%)

HUM Humana
$447.44 /

-6.08 (-1.34%)

HPQ HP Inc.
$40.32 /

+1.56 (+4.02%)

GDRX GoodRx
$7.51 /

-0.45 (-5.65%)

FB Meta Platforms
$188.59 /

-4.965 (-2.57%)

DAL Delta Air Lines
$39.53 /

-2.16 (-5.18%)

CRM Salesforce
$176.04 /

+15.44 (+9.61%)

CPRI Capri Holdings
$49.31 /

+0.55 (+1.13%)

APPS Digital Turbine
$19.65 /

-5.82 (-22.85%)

AMBA Ambarella
$83.59 /

-1.64 (-1.92%)

AFRM Affirm
$24.31 /

-4.15 (-14.58%)

AAPL Apple
$148.68 /

-0.13 (-0.09%)

On The Fly
What You Missed On Wall Street This Morning » 12:10
06/01/22
06/01
12:10
06/01/22
12:10
BITF

Bitfarms

$1.89 /

-0.135 (-6.67%)

, CRM

Salesforce

$176.91 /

+16.31 (+10.16%)

, HPQ

HP Inc.

$39.75 /

+0.99 (+2.55%)

, SPGI

S&P Global

$337.39 /

-12.56 (-3.59%)

, DAL

Delta Air Lines

$39.67 /

-2.02 (-4.85%)

, OPA

Magnum Opus Acquisition

$9.79 /

-0.045 (-0.46%)

, RBAC

RedBall Acquisition

$9.95 /

+0.57 (+6.08%)

, TPX

Tempur Sealy

$24.99 /

-1.385 (-5.25%)

, VRTX

Vertex Pharmaceuticals

$267.07 /

-1.42 (-0.53%)

, BPMC

Blueprint Medicines

$55.22 /

+0.34 (+0.62%)

, GDRX

GoodRx

$7.36 /

-0.6 (-7.54%)

, MDT

Medtronic

$96.53 /

-3.64 (-3.63%)

, AAPL

Apple

$148.33 /

-0.48 (-0.32%)

, ENOB

Enochian Biosciences

$3.66 /

-1.595 (-30.38%)

, AFRM

Affirm

$24.33 /

-4.13 (-14.51%)

, SQ

Block

$82.73 /

-4.76 (-5.44%)

, TSLA

Tesla

$737.88 /

-20.13 (-2.66%)

, TWTR

Twitter

$39.51 /

-0.23 (-0.58%)

, META

Meta Platforms

/

+

, FB

Meta Platforms

$193.20 /

-0.355 (-0.18%)

, CPRI

Capri Holdings

$49.03 /

+0.27 (+0.55%)

, VSCO

Victoria's Secret

$43.57 /

+2.295 (+5.56%)

, AMBA

Ambarella

$82.77 /

-2.46 (-2.89%)

, APPS

Digital Turbine

$19.97 /

-5.5 (-21.59%)

, HUM

Humana

$446.94 /

-6.58 (-1.45%)

, CMAX

CareMax

$5.30 /

+0.62 (+13.25%)

, NIO

Nio

$17.96 /

+0.55 (+3.16%)

, BARK

Bark

$2.17 /

-0.29 (-11.79%)

, LX

LexinFintech

$1.88 /

-0.135 (-6.70%)

Get caught up quickly on…

ShowHide Related Items >><<
VSCO Victoria's Secret
$43.57 /

+2.295 (+5.56%)

VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

TWTR Twitter
$39.51 /

-0.23 (-0.58%)

TSLA Tesla
$737.88 /

-20.13 (-2.66%)

TPX Tempur Sealy
$24.99 /

-1.385 (-5.25%)

SQ Block
$82.73 /

-4.76 (-5.44%)

SPGI S&P Global
$337.39 /

-12.56 (-3.59%)

RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

OPA Magnum Opus Acquisition
$9.79 /

-0.045 (-0.46%)

NIO Nio
$17.96 /

+0.55 (+3.16%)

META Meta Platforms
/

+

MDT Medtronic
$96.53 /

-3.64 (-3.63%)

LX LexinFintech
$1.88 /

-0.135 (-6.70%)

HUM Humana
$446.94 /

-6.58 (-1.45%)

HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

GDRX GoodRx
$7.36 /

-0.6 (-7.54%)

FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

ENOB Enochian Biosciences
$3.66 /

-1.595 (-30.38%)

DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

CPRI Capri Holdings
$49.03 /

+0.27 (+0.55%)

CMAX CareMax
$5.30 /

+0.62 (+13.25%)

BPMC Blueprint Medicines
$55.22 /

+0.34 (+0.62%)

BITF Bitfarms
$1.89 /

-0.135 (-6.67%)

BARK Bark
$2.17 /

-0.29 (-11.79%)

APPS Digital Turbine
$19.97 /

-5.5 (-21.59%)

AMBA Ambarella
$82.77 /

-2.46 (-2.89%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

AAPL Apple
$148.33 /

-0.48 (-0.32%)

BITF Bitfarms
$1.89 /

-0.135 (-6.67%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

06/01/22 RBC Capital
Salesforce margin outlook overshadowed lower revenue guide, says RBC Capital
06/01/22 BMO Capital
Salesforce price target lowered to $225 from $260 at BMO Capital
06/01/22 Stifel
Salesforce price target lowered to $250 from $300 at Stifel
06/01/22 Deutsche Bank
Salesforce price target lowered to $260 from $300 at Deutsche Bank
HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

06/01/22 Morgan Stanley
Morgan Stanley stays Underweight on HP Inc. after Q2 report
06/01/22 Citi
HP Inc. price target raised to $40 from $38 at Citi
06/01/22 Barclays
HP Inc. price target raised to $32 from $29 at Barclays
05/25/22 JPMorgan
HP Inc. price target lowered to $39 from $41 at JPMorgan
SPGI S&P Global
$337.39 /

-12.56 (-3.59%)

05/04/22 BMO Capital
S&P Global price target lowered to $433 from $462 at BMO Capital
05/04/22 Deutsche Bank
S&P Global price target lowered to $483 from $515 at Deutsche Bank
05/04/22 Credit Suisse
S&P Global price target lowered to $425 from $495 at Credit Suisse
05/04/22 UBS
S&P Global price target lowered to $441 from $486 at UBS
DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

06/01/22 Goldman Sachs
Delta Air Lines price target raised to $45 from $44 at Goldman Sachs
04/26/22 Northland
SpaceX's Starlink deal with Hawaiian highlights risk for Gogo, says Northland
04/22/22 Morgan Stanley
United Airlines price target raised to $67 from $62 at Morgan Stanley
04/22/22 JPMorgan
Delta Air Lines price target raised to $70 from $69 at JPMorgan
OPA Magnum Opus Acquisition
$9.79 /

-0.045 (-0.46%)

03/01/22 Benchmark
Magnum Opus Acquisition initiated with a Buy at Benchmark
12/15/21 Cantor Fitzgerald
Magnum Opus Acquisition price target raised to $14.50 from $10.00 at Cantor Fitzgerald
10/21/21 Cantor Fitzgerald
Magnum Opus Acquisition initiated with an Overweight at Cantor Fitzgerald
RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

TPX Tempur Sealy
$24.99 /

-1.385 (-5.25%)

06/01/22 Piper Sandler
Tempur Sealy downgraded to Neutral from Overweight at Piper Sandler
04/12/22 Loop Capital
Tempur Sealy price target lowered to $28 from $35 at Loop Capital
04/06/22 Raymond James
Tempur Sealy price target lowered to $38 from $45 at Raymond James
04/01/22 Piper Sandler
Tempur Sealy price target lowered to $34 from $40 at Piper Sandler
VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

06/01/22 Maxim
Maxim upgrades Vertex Pharmaceuticals to Buy as company expands beyond CF
06/01/22 Maxim
Vertex Pharmaceuticals upgraded to Buy from Hold at Maxim
05/23/22 Piper Sandler
Piper Sandler remains bullish on Catalyst after sale of complement portfolio
05/23/22 SVB Leerink
Vertex Pharmaceuticals initiated with a Market Perform at SVB Leerink
BPMC Blueprint Medicines
$55.22 /

+0.34 (+0.62%)

06/01/22 Jefferies
Blueprint Medicines raised to Buy at Jefferies after survey on Ayvakit in ISM
06/01/22 Jefferies
Blueprint Medicines upgraded to Buy from Hold at Jefferies
05/18/22 Piper Sandler
Blueprint Medicines price target lowered to $65 from $84 at Piper Sandler
05/04/22 Baird
Blueprint Medicines price target lowered to $96 from $123 at Baird
GDRX GoodRx
$7.36 /

-0.6 (-7.54%)

06/01/22 Baird
Baird downgrades GoodRx to Neutral amid disruption at Kroger
06/01/22 Baird
GoodRx downgraded to Neutral from Outperform at Baird
05/16/22 Baird
Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
05/12/22 Wells Fargo
GoodRx price target lowered to $9 from $20 at Wells Fargo
MDT Medtronic
$96.53 /

-3.64 (-3.63%)

06/01/22 Atlantic Equities
Medtronic downgraded to Neutral from Overweight at Atlantic Equities
05/31/22 Raymond James
Medtronic price target lowered to $109 from $116 at Raymond James
05/31/22 Truist
Medtronic price target lowered to $111 from $121 at Truist
05/27/22 RBC Capital
Medtronic price target lowered to $122 from $135 at RBC Capital
AAPL Apple
$148.33 /

-0.48 (-0.32%)

06/01/22 Macquarie
Digital Turbine price target lowered to $40 from $70 at Macquarie
05/27/22 JPMorgan
iPhone China shipments in April below seasonal, says JPMorgan
05/25/22 Loop Capital
Loop Capital sees consensus for Apple's iPhone revenue in second half as low
05/24/22 BofA
Apple App Store growth has re-accelerated modestly, says BofA
ENOB Enochian Biosciences
$3.66 /

-1.595 (-30.38%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

05/23/22 Mizuho
April delinquency trends promising for Affirm, says Mizuho
05/17/22 Mizuho
Affirm price target lowered to $50 from $79 at Mizuho
05/16/22 Barclays
Affirm price target lowered to $35 from $65 at Barclays
05/13/22 RBC Capital
Affirm price target lowered to $48 from $58 at RBC Capital
SQ Block
$82.73 /

-4.76 (-5.44%)

06/01/22 Piper Sandler
App downloads for Block's Cash App strong, says Piper Sandler
05/24/22 Morgan Stanley
Morgan Stanley upgrades Marqeta to Overweight on attractive entry point
05/23/22 Truist
Block price target lowered to $145 from $165 at Truist
05/23/22 Deutsche Bank
Block price target lowered to $155 from $180 at Deutsche Bank
TSLA Tesla
$737.88 /

-20.13 (-2.66%)

06/01/22 Goldman Sachs
Tesla price target lowered to $1,000 from $1,200 at Goldman Sachs
05/31/22 Mizuho
Tesla shutdown in Shanghai a near-term headwind, says Mizuho
05/27/22 Credit Suisse
Tesla pullback brings attractive entry point, says Credit Suisse
05/26/22 Jefferies
Jefferies cuts Tesla price target on governance risk, challenging market
TWTR Twitter
$39.51 /

-0.23 (-0.58%)

05/24/22 Jefferies
Twitter price target lowered to $40 from $48 at Jefferies
05/24/22 Wedbush
More fireworks expected heading into Twitter shareholder meeting, says Wedbush
05/24/22 KeyBanc
Snap price target lowered to $27 from $45 at KeyBanc
05/24/22 Bernstein
Bernstein says Tesla-Twitter saga far from over, discusses funding requirements
META Meta Platforms
/

+

05/10/22 BMO Capital
Yelp price target lowered to $37 from $42 at BMO Capital
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
03/25/22 UBS
Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS
FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

06/01/22 Morgan Stanley
Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
06/01/22 Morgan Stanley
Meta Platforms price target lowered to $300 from $330 at Morgan Stanley
05/24/22 Jefferies
Meta Platforms price target lowered to $310 from $330 at Jefferies
05/24/22 BofA
Snap price target lowered to $30 from $50 at BofA
CPRI Capri Holdings
$49.03 /

+0.27 (+0.55%)

04/19/22 OTR Global
Tapestry view downgraded to Mixed from Positive at OTR Global
04/19/22 Barclays
Capri Holdings price target raised to $74 from $72 at Barclays
04/05/22 Wells Fargo
Capri Holdings price target lowered to $85 from $95 at Wells Fargo
04/01/22 Barclays
Capri Holdings price target lowered to $72 from $85 at Barclays
VSCO Victoria's Secret
$43.57 /

+2.295 (+5.56%)

06/01/22 JPMorgan
Victoria's Secret price target lowered to $57 from $71 at JPMorgan
06/01/22 Wells Fargo
Victoria's Secret price target lowered to $60 from $70 at Wells Fargo
05/16/22 JPMorgan
Victoria's Secret price target lowered to $71 from $86 at JPMorgan
04/05/22 Wells Fargo
Victoria's Secret price target lowered to $70 from $75 at Wells Fargo
AMBA Ambarella
$82.77 /

-2.46 (-2.89%)

06/01/22 Craig-Hallum
Ambarella price target lowered to $100 from $170 at Craig-Hallum
06/01/22 Needham
Ambarella price target lowered to $120 from $175 at Needham
06/01/22 Morgan Stanley
Ambarella price target lowered to $114 from $122 at Morgan Stanley
06/01/22 Cowen
Ambarella price target lowered to $135 from $180 at Cowen
APPS Digital Turbine
$19.97 /

-5.5 (-21.59%)

06/01/22 Craig-Hallum
Digital Turbine price target lowered to $85 from $105 at Craig-Hallum
06/01/22 Oppenheimer
Digital Turbine price target lowered to $40 from $117 at Oppenheimer
02/16/22 Roth Capital
Roth says Google news creates more unwarranted noise around Digital Turbine
HUM Humana
$446.94 /

-6.58 (-1.45%)

05/26/22 Bernstein
Humana resumed with a Market Perform at Bernstein
04/28/22 Wells Fargo
Humana price target raised to $512 from $491 at Wells Fargo
04/13/22 UBS
Humana upgraded to Buy from Neutral at UBS
04/07/22 Truist
Humana price target raised to $490 from $460 at Truist
CMAX CareMax
$5.30 /

+0.62 (+13.25%)

05/11/22 Cowen
CareMax price target lowered to $8 from $11 at Cowen
01/07/22 UBS
CareMax initiated with a Buy at UBS
12/01/21 Piper Sandler
Piper Sandler remains buyer of CareMax after management meeting
11/15/21 Piper Sandler
Piper remains buyer of CareMax, likes share setup into Q4
NIO Nio
$17.96 /

+0.55 (+3.16%)

05/23/22 Mizuho
Nio could be back to pre-shutdown levels by June, says Mizuho
05/16/22 BofA
Nio upgraded to Buy at BofA on 'brighter' second half view
05/16/22 BofA
Nio upgraded to Buy from Neutral at BofA
05/02/22 Morgan Stanley
Nio's April sales 'crimped' by lockdowns, says Morgan Stanley
BARK Bark
$2.17 /

-0.29 (-11.79%)

06/01/22 Canaccord
Original Bark Company price target lowered to $8 from $10 at Canaccord
02/11/22 Canaccord
Original Bark Company price target lowered to $12 from $16 at Canaccord
11/18/21 Citi
Original Bark Company price target lowered to $14 from $16 at Citi
06/28/21 Citi
Original Bark Company initiated with a Buy at Citi
LX LexinFintech
$1.88 /

-0.135 (-6.70%)

06/01/22 CLSA
LexinFintech downgraded to Sell from Outperform at CLSA
05/31/22 Citi
LexinFintech downgraded to Neutral from Buy at Citi
12/20/21 UBS
LexinFintech downgraded to Neutral from Buy at UBS
08/26/21 DBS Bank
LexinFintech downgraded to Hold from Buy at DBS Bank
VSCO Victoria's Secret
$43.57 /

+2.295 (+5.56%)

VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

TWTR Twitter
$39.51 /

-0.23 (-0.58%)

TSLA Tesla
$737.88 /

-20.13 (-2.66%)

TPX Tempur Sealy
$24.99 /

-1.385 (-5.25%)

SQ Block
$82.73 /

-4.76 (-5.44%)

SPGI S&P Global
$337.39 /

-12.56 (-3.59%)

NIO Nio
$17.96 /

+0.55 (+3.16%)

MDT Medtronic
$96.53 /

-3.64 (-3.63%)

HUM Humana
$446.94 /

-6.58 (-1.45%)

HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

GDRX GoodRx
$7.36 /

-0.6 (-7.54%)

FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

CPRI Capri Holdings
$49.03 /

+0.27 (+0.55%)

CMAX CareMax
$5.30 /

+0.62 (+13.25%)

BPMC Blueprint Medicines
$55.22 /

+0.34 (+0.62%)

BITF Bitfarms
$1.89 /

-0.135 (-6.67%)

BARK Bark
$2.17 /

-0.29 (-11.79%)

APPS Digital Turbine
$19.97 /

-5.5 (-21.59%)

AMBA Ambarella
$82.77 /

-2.46 (-2.89%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

AAPL Apple
$148.33 /

-0.48 (-0.32%)

VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

TWTR Twitter
$39.51 /

-0.23 (-0.58%)

TSLA Tesla
$737.88 /

-20.13 (-2.66%)

SQ Block
$82.73 /

-4.76 (-5.44%)

OPA Magnum Opus Acquisition
$9.79 /

-0.045 (-0.46%)

NIO Nio
$17.96 /

+0.55 (+3.16%)

META Meta Platforms
/

+

MDT Medtronic
$96.53 /

-3.64 (-3.63%)

HUM Humana
$446.94 /

-6.58 (-1.45%)

HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

ENOB Enochian Biosciences
$3.66 /

-1.595 (-30.38%)

DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

AAPL Apple
$148.33 /

-0.48 (-0.32%)

VSCO Victoria's Secret
$43.57 /

+2.295 (+5.56%)

VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

TSLA Tesla
$737.88 /

-20.13 (-2.66%)

TPX Tempur Sealy
$24.99 /

-1.385 (-5.25%)

SQ Block
$82.73 /

-4.76 (-5.44%)

SPGI S&P Global
$337.39 /

-12.56 (-3.59%)

OPA Magnum Opus Acquisition
$9.79 /

-0.045 (-0.46%)

NIO Nio
$17.96 /

+0.55 (+3.16%)

META Meta Platforms
/

+

MDT Medtronic
$96.53 /

-3.64 (-3.63%)

HUM Humana
$446.94 /

-6.58 (-1.45%)

HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

GDRX GoodRx
$7.36 /

-0.6 (-7.54%)

FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

CPRI Capri Holdings
$49.03 /

+0.27 (+0.55%)

BITF Bitfarms
$1.89 /

-0.135 (-6.67%)

BARK Bark
$2.17 /

-0.29 (-11.79%)

APPS Digital Turbine
$19.97 /

-5.5 (-21.59%)

AMBA Ambarella
$82.77 /

-2.46 (-2.89%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

AAPL Apple
$148.33 /

-0.48 (-0.32%)

VSCO Victoria's Secret
$43.57 /

+2.295 (+5.56%)

VRTX Vertex Pharmaceuticals
$267.07 /

-1.42 (-0.53%)

TWTR Twitter
$39.51 /

-0.23 (-0.58%)

TSLA Tesla
$737.88 /

-20.13 (-2.66%)

TPX Tempur Sealy
$24.99 /

-1.385 (-5.25%)

SQ Block
$82.73 /

-4.76 (-5.44%)

SPGI S&P Global
$337.39 /

-12.56 (-3.59%)

RBAC RedBall Acquisition
$9.95 /

+0.57 (+6.08%)

NIO Nio
$17.96 /

+0.55 (+3.16%)

META Meta Platforms
/

+

MDT Medtronic
$96.53 /

-3.64 (-3.63%)

LX LexinFintech
$1.88 /

-0.135 (-6.70%)

HUM Humana
$446.94 /

-6.58 (-1.45%)

HPQ HP Inc.
$39.75 /

+0.99 (+2.55%)

GDRX GoodRx
$7.36 /

-0.6 (-7.54%)

FB Meta Platforms
$193.20 /

-0.355 (-0.18%)

DAL Delta Air Lines
$39.67 /

-2.02 (-4.85%)

CRM Salesforce
$176.91 /

+16.31 (+10.16%)

CPRI Capri Holdings
$49.03 /

+0.27 (+0.55%)

BITF Bitfarms
$1.89 /

-0.135 (-6.67%)

BARK Bark
$2.17 /

-0.29 (-11.79%)

APPS Digital Turbine
$19.97 /

-5.5 (-21.59%)

AMBA Ambarella
$82.77 /

-2.46 (-2.89%)

AFRM Affirm
$24.33 /

-4.13 (-14.51%)

AAPL Apple
$148.33 /

-0.48 (-0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.